Biomarkers can be described as measurable and quantifiable indicators of normal
physiological function, disease states or of the body's response to therapeutics.
The Biomarkers Definition Working Group (2001) classified
five different types of biomarker based on function
diagnostic
Prognostic
Predictive
Staging
Surrogate endpoints
Biomarkers are present in bodily fluids
Blood and blood fractions
(serum, plasma, buffy coat)
Urine
saliva
Tissues
National Cancer Institute defines a tumour marker as a
substance that may be found in tumour tissue or released
from a tumour into the blood or other body fluids
Imaging derived biomarkers
Aim: to predict metastatic spread of tumours
which causes the vast majority of cancer
related death
the primary tumour is examined for biomarkers which could
predict the metastatic event occurring many years later
Overview
starting point for imaging process: Tissue microarrays
take small pieces of tumour tissue from individual patients
and look for expression of markers across hundreds of
tumour specimens simultaneously
In vivo imaging used to monitor tumour growth or the response of tumour to treatment
New imaging technologies are increasingly being used to understand the in vivo behaviour of cancers
Omic approaches provide and overview of biomarkers in cancer
large bottleneck in converting these candidate biomarkers into clinical use
Imaging has the ability to take this omic-generated information further,
allowing us to see the actual activity and location of the biomarkers in vivo.
Antibody based proteomics (in vitro)
forefront of omic technologies
Antibodies are useful tools for quantifying protein expression and detecting antigens for biomarkers
using bioinformatics, genes of interest are identified and then antibodies are used to profile tissue
s is then combined with vision approaches to develop an assay
Antibodies form the basis of tissue microarrays which
area platform for high throughput pathology
sections of FFPE taken
looked at under microscope to confirm tissue is cancerous
additional staining is performed to see if the tissue is expressing particular proteins
Tiny cores are taken from all the tumour samples
put on master block
RNA expression analysis is examined with respect to its morphology
Digital pathology used to help this system
major advance from the highly subjective and time
consuming method of viewing slides under a
microscope
takes a slide, scans it and creates a digital image
uses computer based vision approach rather than relying on pathologist to manually examine it
moves being made toward an in vivo approach
advances in clinical imaging are improving how cancer is understood at a
systems level and enable doctors to not only locate a tumour but examine
its biological processes
Imaging systems grouped by
energy used to derive the visual information
X-rays
positrons
photons
sound waves
spatial resolution obtained
macroscopic
widespread use of macroscopic imaging systems that
provide anatomical and physiological information
Computed Tomography (CT)
Magnetic resonance imaging (MRI)
ultrasound
microscopic
type of information obtained
anatomical
physiological
cellular
molecular
systems that obtain molecular information are only beginning to be used clinically
positron emission tomography (PET)
single-photon emission CT (SPECT)
fluorescence based imaging
nuclear imaging
based on administration and detection of decaying radioisotopes in vivo.
These radioisotopes combine with biologically active compounds to
form radiopharmaceuticals which target specific molecular events
Decaying radioisotopes emit a positron or gamma ray which
produce high-energy photons
can be detected using PET or SPECT
PET
a contrast agent or tracer based imaging method
most commonly used tracer is 18F-FDG (flurodeoxyglucose)
reflects glucose uptake and metabolism
disadvantage:
PET tracer agents typically
have a short half life
because of this there is a requirement for scanners
to be located close to a cyclotron
optical imaging
based on photons travelling through tissue and their interactions
fluorescence based
fluorescence refers to the property of certain molecules to absorb light at a
specific wavelength and emit light of a longer wavelength after a brief interval
discovered in the 19th century
first application was in 1924 when the autofluorescence of endogenous
porphyrins were observed in tumour illuminated with ultraviolet light
macroscopic
systems rely on photographic principles to collect images in low light
microscopic
used to examine the activity of cells in biological settings including tumours
possible to analyse multiple cell types at the same time and in solid tissues
Examples
Multiphoton microscopy imaging systems
yield 3D information from light emitted by fluorescently labelled objects
Intravital multiphoton microscopy
derives quantitative parameters of intravascular and interstitial cell migration
cells investigated in lymph nodes, cranial bone marrow,
and organs harbouring orthotopic cancers
Tomographic fluorescence systems
reconstruct 3D maps of fluorochromes on the basis of algorithms
enable fluorescent proteins or genetically modified cells to be tracked in vivo
non-fluorescence based
In vivo techniques can also be applied to the anti-cancer drug development process
Photodynamic therapy is a treatment where a fluorescent photosensitiser (e.g. ADPM) is administered to the patient
The drug then preferentially accumulates in tumour cells where it can be illuminated with a light so that it becomes toxic to targeted malignant cells
this process has the advantage of only harming toxic cells so it has a low mutagenic potential